Correction: Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model

Hassan, Adam S.; Zelt, Nicholas; Perera, Dilhan J.; Xing, Li; Ndao, Momar; Ward, Brian J.

doi:10.1371/journal.pntd.0009936

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2022) reviewed the characteristics and progress of four potential vaccine candidates at various stages of clinical development [ 83 ]. The vaccines target four proteins: rSh28GST, a recombinant S. haematobium glutathione S-transferase; rSm14, a recombinant S. mansoni fatty acid binding protein (FABP); Sm-TSP-2, one of the most abundant tetraspanins of the S. mansoni tegument; and Sm-p80, a second S. mansoni surface protein expressed in all life stages of the parasite [ 84 ]. A One Health approach is also being considered, which would involve the development of a vaccine for cattle [ 85 ].…”

Section: Current Therapies and Additional Strategies To Be Consideredmentioning

confidence: 99%

Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis

Ponzo,

Midiri,

Manno

et al. 2024

EuJMI

View full text Add to dashboard Cite

Schistosomiasis is a neglected tropical disease that is prevalent in low- and middle-income countries. There are five human pathogenic species, of which Schistosoma haematobium, Schistosoma mansoni and Schistosoma japonicum are the most prevalent worldwide and cause the greatest burden of disease in terms of mortality and morbidity. In addition, hybrid schistosomes have been identified through molecular analysis. Human infection occurs when cercariae, the larval form of the parasite, penetrate the skin of people while bathing in contaminated waters such as lakes and rivers. Schistosomiasis can cause both urogenital and intestinal symptoms. Urogenital symptoms include haematuria, bladder fibrosis, kidney damage, and an increased risk of bladder cancer. Intestinal symptoms may include abdominal pain, sometimes accompanied by diarrhoea and blood in the stool. Schistosomiasis affects more than 250 million people and causes approximately 70 million Disability-Adjusted Life Years (DALYs), mainly in Africa, South America, and Asia. To control infection, it is essential to establish sensitive and specific diagnostic tests for epidemiological surveillance and morbidity reduction. This review provides an overview of schistosomiasis, with a focus on available diagnostic tools for Schistosoma spp. Current molecular detection methods and progress in the development of new diagnostics for schistosomiasis infection are also discussed.

show abstract

Section: Current Therapies and Additional Strategies To Be Consideredmentioning

confidence: 99%

Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis

Ponzo,

Midiri,

Manno

et al. 2024

EuJMI

View full text Add to dashboard Cite

show abstract

Correction: Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model

Cited by 1 publication

References 1 publication

Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis

Insights into the epidemiology, pathogenesis, and differential diagnosis of schistosomiasis

Contact Info

Product

Resources

About